Business Wire

Dfns Secures $16M to Expand its Crypto Wallet Infrastructure for Finance

14.1.2025 17:00:00 EET | Business Wire | Press release

Share

Dfns, the leading wallet-as-a-service platform for crypto assets, has successfully closed a $16 million Series A, led by Further Ventures, the venture arm of Abu Dhabi’s largest sovereign wealth fund, ADQ. This round also saw participation from historic investors such as White Star Capital, Hashed, Semantic, Techstars, and Bpifrance, alongside new backers including Motive Partners, Wintermute, and Motier Ventures.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114288142/en/

(Photo: Business Wire)

Our Institutional Focus Paid Off

Two years ago, Dfns made a strategic up-market move focusing mainly on institutional clients. The company’s vision has remained steadfast: institutional investors hold the key to driving crypto adoption as they have the lion’s share of the global liquidity. To appeal to them, Dfns prioritized uncompromising bank-grade security, aligning with standard traditional financial systems and leveraging state-of-the-art technology to surpass expectations. As crypto assets gain in value, the risks and scrutiny surrounding them grow. By positioning itself as the most secure blockchain wallet infrastructure, Dfns has become the infrastructure of choice for trusted institutions navigating crypto and shaping its future inside finance.

Dfns has a reputation for transparency, reliability and security, with trust-building initiatives: industry-leading certifications, regulatory licenses, robust insurance, independent audits, and partnerships with global leaders. Its hallmark clients include Fidelity, Bridge (Stripe), Zodia Custody (Standard Chartered), Tungsten Custody (ADQ), and 130+ fintechs worldwide.

Strategic Use of Funds

Following its $13 million seed round in 2022, this new Series A funding will enable Dfns to accelerate the distribution of its multichain wallet infrastructure in 2025. The focus will be on expanding adoption among banks, payment services, trading platforms, investment apps, tokenization projects, government and corporate treasuries, and fund administrators, with an emphasis on the EU, UK, UAE, and US markets.

“We have a clear plan,” said Clarisse Hagège, CEO of Dfns. “Crypto can be unpredictable, so we’ve learned to prioritize sustainable growth over rapid expansion. We’re not looking to scale our workforce aggressively; instead, we aim to grow from 25 to 35 employees by year-end, provided we meet our targets and the market remains stable. Our focus is to deliver world-class infrastructure for our fintech clients. They demand bank-grade security, smarter transaction management, direct integrations, and better user and developer experiences. This is what we do best, and it’s what we’ll keep delivering.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114288142/en/

Contacts

Press:

Christopher Grilhault des Fontaines
chris@dfns.co

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye